達爾奈多

達爾奈多
INN： dalzanemdor
臨床資料
其他名稱	SAGE-718
法律規範狀態
法律規範	Investigational;
識別資訊
	IUPAC命名法 (3S,8R,9S,10R,13R,14S,17R)-3,13-Dimethyl-17-[(2R,5S)-6,6,6-trifluoro-5-hydroxy-5-methylhexan-2-yl]-2,4,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; ;
CAS號	2311911-06-3
PubChem CID	134452289;
KEGG	D12788;
ChEMBL	ChEMBL5197411;
化學資訊
化學式	C26H41F3O2
摩爾質量	442.61 g·mol−1
3D模型（JSmol（英語：JSmol））	交互式圖像;
	SMILES C[C@H](CC[C@@](C)(C(F)(F)F)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@H]3CC[C@](C4)(C)O)C;
	InChI InChI=InChI=1S/C26H41F3O2/c1-16(9-14-25(4,31)26(27,28)29)21-7-8-22-20-6-5-17-15-23(2,30)12-10-18(17)19(20)11-13-24(21,22)3/h5,16,18-22,30-31H,6-15H2,1-4H3/t16-,18+,19-,20-,21-,22+,23+,24-,25+/m1/s1; Key:RTBRKGVJBGKMFF-YMEFNWBESA-N;

達爾奈多（INN：dalzanemdor；開發代號：SAGE-718）是一種正在研究用於治療神經系統疾病和認知障礙的實驗性藥物，^[1]是神經甾體（英語：neurosteroid）腦甾醇的類似物。^[2]截至2022年，它在阿茲海默症、^[3]^[4]^[5]柏金遜症和亨丁頓舞蹈症^[6]^[7]的治療上處於二期臨床研究階段。

參考文獻

^ Hill MD, Blanco MJ, Salituro FG, Bai Z, Beckley JT, Ackley MA, et al. SAGE-718: A First-in-Class N-Methyl-d-Aspartate Receptor Positive Allosteric Modulator for the Potential Treatment of Cognitive Impairment. Journal of Medicinal Chemistry. July 2022, 65 (13): 9063–9075. PMID 35785990. S2CID 250250073. doi:10.1021/acs.jmedchem.2c00313.
^ SAGE-718. ALZFORUM. [2024-09-11]. （原始內容存檔於2023-12-20）.
^ Shapiro L. #AAN2022 – SAGE-718 May Help With Cognitive Function in Alzheimer's. BioNews, Inc. 2022-04-05 [2024-09-11]. （原始內容存檔於2023-12-20）.
^ SAGE-718 in Patients With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease: Results From the Phase 2 LUMINARY Study (PDF). American Academy of Neurology (AAN) 74th Annual Meeting Abstract. [2024-09-11]. （原始內容存檔於2022-04-05）.
^ Castañeda R. Regulatory roundup: Sage Alzheimer's asset likely to progress after Phase IIa completion. Clinical Trials Arena. 2021-11-16 [2022-07-13]. （原始內容存檔於2022-05-28）.
^ Sage Therapeutics Provides Important Update On The Clinical Development Program For Sage's Investigational Drug, SAGE-718.. Huntington's Disease Society of America. 2022-02-22 [2024-09-11]. （原始內容存檔於2024-12-02）.
^ Wexler M. SAGE-718 on FDA Fast Track as Potential Huntington's Disease Therapy. BioNews, Inc. 2021-09-21 [2024-09-11]. （原始內容存檔於2024-11-30）.

這是一篇作用於神經系統的藥品小作品。您可以透過編輯或修訂擴充其內容。